CD2AP inhibits metastasis in gastric cancer by promoting cellular adhesion and cytoskeleton assembly

Area of Science:

• Oncology
• Cell Biology
• Molecular Biology

Background:

• Diffuse gastric cancer (DGC) presents a significant therapeutic challenge due to a lack of effective treatments.
• Alterations in the cellular cytoskeleton and intercellular adhesion are implicated in DGC progression.
• CD2-associated protein (CD2AP) is a key regulator of cytoskeleton dynamics and cell adhesion.

Purpose of the Study:

• To investigate the expression and clinical significance of CD2AP in gastric cancer (GC).
• To elucidate the molecular mechanisms underlying CD2AP's role in GC progression.

Main Methods:

• Immunohistochemistry was performed on 620 patient tissue samples.
• In vitro experiments involved forced expression and depletion of CD2AP in GC cells.
• Immunofluorescence analysis was used to study CD2AP's interaction with F-actin and CAPZA1.

Main Results:

• CD2AP expression was found to be significantly downregulated in DGC tissues.
• Low CD2AP levels correlated with poor patient prognosis.
• Forced CD2AP expression reduced GC cell migration and invasion, while CD2AP depletion increased these processes.
• CD2AP was shown to promote cell adhesion and influence cytoskeleton assembly via CAPZA1 interaction.

Conclusions:

• CD2AP downregulation is associated with GC progression and poor prognosis.
• Upregulation of CD2AP can inhibit GC metastasis by modulating cell adhesion and cytoskeleton dynamics.
• CD2AP represents a potential novel biomarker for GC prognosis and a therapeutic target.